1.陆军军医大学(第三军医大学)第二附属医院,营养科,重庆
2.陆军军医大学(第三军医大学)第二附属医院,普通外科,重庆
XIAO Weidong, E-mail: xiaoweidong@tmmu.edu.cn
WANG Jian, E-mail: wangjian xq@tmmu.edu.cn;
Published:30 January 2025,
Received:05 September 2024,
Revised:16 October 2024,
移动端阅览
WANG WEI, HAN BEN, SUN LIHUA, et al. β-glucan attenuates intestinal ischemia-reperfusion injury in mice by promoting glucagon-like peptide-1 secretion. [J]. Journal of army medical university, 2025, 47(2): 112-121.
WANG WEI, HAN BEN, SUN LIHUA, et al. β-glucan attenuates intestinal ischemia-reperfusion injury in mice by promoting glucagon-like peptide-1 secretion. [J]. Journal of army medical university, 2025, 47(2): 112-121. DOI: 10.16016/j.2097-0927.202409020.
目的
2
探讨β-葡聚糖(β-glucan, BG)通过调控胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)分泌对肠缺血再灌注(intestinal ischemia reperfusion, II/R)损伤作用及机制。
方法
2
将18只6~8周雄性C57BL/6小鼠按随机数字表法分为3组(
n
=6):假手术组、II/R组、II/R+BG组,假手术组和II/R组正常饮食,II/R+BG组造模前2周饮用水中含0.1 mg/mL BG,建模后,HE染色用于观察肠道形态变化,RT-qPCR评估与肠道屏障损伤相关的分子(Occludin、ZO-1和Claudin-1)。将12只6~8周龄雄性C57BL/6小鼠按随机数字表法分为2组(
n
=6):Water组、BG组,Water组正常饮食,BG组饮用水含中0.1 mg/mL BG。分别用ELISA、免疫荧光法以及RT-PCR检测与GLP-1表达相关的分子(Gcg、Pcsk1/2、GIP和Foxa2),探究0.1mg/mL BG治疗对正常小鼠血清和肠组织中GLP-1水平的影响。将另外12只6~8周龄雄性C57BL/6小鼠按随机数字表法分为2组(
n
=6):II/R组造模前腹腔注射生理盐水,连续3 d,每12 h注射1次,II/R+利拉鲁肽(liraglutide, LLT)组造模前腹腔注射0.2 μg/g LLT,连续3 d,每12 h注射1次,建模后,HE染色用于观察肠道形态变化,RT-qPCR和Western印迹用于评估与肠道屏障损伤相关的分子(Occludin、ZO-1和Claudin-1)。12只6~8周龄雄性C57BL/6小鼠饮水中加入BG预处理2周,按随机数字表法分为2组(
n
=6):II/R+BG组、II/R+BG+Ex9-39(GLP-1R拮抗剂)组(建模前1 h腹膜注射2 μg/g Ex9-39),造模后采用上述方法评估肠屏障损伤情况。
结果
2
与假手术组相比,II/R组诱导Occludin、ZO-1和Claudin-1的mRNA水平显著降低,Chiu’s评分升高(
P
<
0.05)。而II/R+BG组3种分子的mRNA水平明显高于II/R组,Chiu’s评分低于II/R组(
P
<
0.05)。与Water组相比,BG组显著增强了正常小鼠血清和肠道中GLP-1的分泌,并改善了GLP-1相关分子的mRNA表达(
P
<
0.05)。GLP-1类似物LLT的干预可以减轻II/R损伤,降低Chiu’s评分,与II/R组相比有统计学差异(
P
<
0.05)。与II/R+BG组相比,II/R+BG+Ex9-39(GLP-1R拮抗剂)组逆转了BG预处理对II/R损伤的保护作用,在Occludin、ZO-1和Claudin-1的表达以及Chiu’s评分方面存在统计学差异(
P
<
0.05)。
结论
2
BG可以通过促进肠道GLP-1分泌减轻II/R后肠黏膜形态和功能损伤。
Objective To investigate the protective effect of β-glucan (BG) against intestinal ischemia reperfusion (II/R) injury by regulating the secretion of glucagon-like peptide-1 (GLP-1). Methods Male C57BL/6 mice (6~8 weeks old) were subjected
and finally
the experiments had sham group
II/R group
II/R+BG group (0.1 mg/mL BG in drinking water for 2 weeks before modeling)
II/
R+liraglutide (LLT
GLP-1 analogue) group (0.2 μg/g LLT injected every 12 hours for 3 consecutive days before modeling)
and II/R+BG+Ex9-39 (GLP-1R antagonist) group (intraperitoneal injection of 2 μg/g Ex9-39 1 h before modeling). After modeling
HE staining was used to observe intestinal morphological changes
and RT-qPCR and Western blotting were employed to evaluate the molecules (Occludin
ZO-1 and Claudin-1) related to intestinal barrier damage. The effect of 0.1 mg/mL BG treatment on the GLP-1 level in the serum and intestinal tissues of normal mice was determined with ELISA and immunofluorescence assay
respectively
and RT-PCR for the molecules related to GLP-1 expression (Gcg
Pcsk1/2
GIP and Foxa2). The effects of LLT and Ex9-39 pretreatment on intestinal morphology and intestinal barrier damage were also determined by morphological observation and expression levels of related molecules. Results II/R induced significant decreases in the mRNA levels of Occludin
ZO-1 and Claudin-1 and increase in Chiu's score when compared with sham control mice (
P
<
0.05). While
the mRNA levels of the 3 molecules were obviously higher and the Chiu's score was lower in the II/R+BG group than the II/R group (
P
<
0.05). BG pretreatment induced notably enhanced secretion of GLP-1 in the serum and intestinal tract of normal mice
and improved the mRNA expression of GLP-1-related molecules (
P
<
0.05). The intervention of GLP-1 analogue LLT could attenuate the II/R damage and decreased Chiu's score
with statistical difference in comparison with the II/R group (
P
<
0.05). GLP-1 receptor antagonist Ex9-39 reversed the protective effects of BG pretreatment against II/R damage
with notably differences in the expression of Occludin
ZO-1 and Claudin-1 and Chiu's score (
P
<
0.05). Conclusion BG can attenuate intestinal mucosal and functional injury after II/R by promoting intestinal GLP-1 secretion.
肠缺血再灌注损伤β-葡聚糖GLP-1肠屏障
intestinal ischaemia-reperfusion injuryβ-glucanglucagon-like peptide-1intestinal barrier
DENG F, ZHAO B C, YANG X, et al. The gut microbiota metabolite capsiate promotes Gpx4 expression by activating TRPV1 to inhibit intestinal ischemia reperfusion-induced ferroptosis[J]. Gut Microbes, 2021, 13(1): 1-21. DOI: 10.1080/19490976.2021.1902719http://dx.doi.org/10.1080/19490976.2021.1902719.
HU J J, DENG F, ZHAO B C, et al. Lactobacillus murinus alleviate intestinal ischemia/reperfusion injury through promoting the release of interleukin-10 from M2 macrophages via Toll-like receptor 2 signaling[J]. Microbiome, 2022, 10(1): 38. DOI: 10.1186/s40168-022-01227-whttp://dx.doi.org/10.1186/s40168-022-01227-w.
MATHEWS R, SHETE V, CHU Y F. The effect of cereal Β-glucan on body weight and adiposity: a review of efficacy and mechanism of action[J]. Crit Rev Food Sci Nutr, 2023, 63(19): 3838-3850. DOI: 10.1080/10408398.2021.1994523http://dx.doi.org/10.1080/10408398.2021.1994523.
CICERO A F G, FOGACCI F, VERONESI M, et al. A randomized placebo-controlled clinical trial to evaluate the medium-term effects of oat fibers on human health: the Beta-glucan effects on lipid profile, glycemia and in testinal health (belt) study[J]. Nutrients, 2020, 12(3): 686. DOI: 10.3390/nu12030686http://dx.doi.org/10.3390/nu12030686.
SUNG M, YOON Y, LEE J. The immunomodulatory effect of β-glucan depends on the composition of the gut microbiota[J]. Foods, 2023, 12(17): 3148. DOI: 10.3390/foods12173148http://dx.doi.org/10.3390/foods12173148.
HAN X Q, LUO R F, YE N J, et al. Research progress on natural β-glucan in intestinal diseases[J]. Int J Biol Macromol, 2022, 219: 1244-1260. DOI: 10.1016/j.ijbiomac. 2022. 08.173http://dx.doi.org/10.1016/j.ijbiomac.2022.08.173.
BALDASSANO S, ACCARDI G, VASTO S. Beta-glucans and cancer: The influence of inflammation and gut peptide[J]. Eur J Med Chem, 2017, 142: 486-492. DOI: 10.1016/j.ejmech.2017.09.013http://dx.doi.org/10.1016/j.ejmech.2017.09.013.
BECK E J, TAPSELL L C, BATTERHAM M J, et al. Oat beta-glucan supplementation does not enhance the effectiveness of an energy-restricted diet in overweight women[J]. Br J Nutr, 2010, 103(8): 1212-1222. DOI: 10.1017/S0007114509992856http://dx.doi.org/10.1017/S0007114509992856.
D’ALESSIO D. Is GLP-1 a hormone: Whether and When?[J]. J Diabetes Invest, 2016, 7(S1): 50-55. DOI: 10.1111/jdi.12466http://dx.doi.org/10.1111/jdi.12466.
LI Q X, GAO H, GUO Y X, et al. GLP-1 and underlying beneficial actions in Alzheimer’s disease, hypertension, and NASH[J]. Front Endocrinol, 2021, 12: 721198. DOI: 10.3389/fendo.2021.721198http://dx.doi.org/10.3389/fendo.2021.721198.
ZHU Q X, LUO Y, WEN Y T, et al. Semaglutide inhibits ischemia/reperfusion-induced cardiomyocyte apoptosis through activating PKG/PKCε/ERK1/2 pathway[J]. Biochem Biophys Res Commun, 2023, 647: 1-8. DOI: 10.1016/j.bbrc.2023.01.049http://dx.doi.org/10.1016/j.bbrc.2023.01.049.
LEBRUN L J, GROBER J. Could glucagon-like peptide-1 be a potential biomarker of early-stage intestinal ischemia?[J]. Biochimie, 2019, 159: 107-111. DOI: 10.1016/j.biochi. 2018.11.009http://dx.doi.org/10.1016/j.biochi.2018.11.009.
MOK J, ADELEKE M O, BROWN A, et al. Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: the BARI-OPTIMISE randomized clinical trial[J]. JAMA Surg, 2023, 158(10): 1003-1011. DOI: 10.1001/jamasurg. 2023.2930http://dx.doi.org/10.1001/jamasurg.2023.2930.
SUZUKI S, AOE S. High β-glucan barley supplementation improves glucose tolerance by increasing GLP-1 secretion in diet-induced obesity mice[J]. Nutrients, 2021, 13(2): 527. DOI: 10.3390/nu13020527http://dx.doi.org/10.3390/nu13020527.
DU B, MEENU M, LIU H Z, et al. A concise review on the molecular structure and function relationship of β-glucan[J]. Int J Mol Sci, 2019, 20(16): 4032. DOI: 10.3390/ijms20164032http://dx.doi.org/10.3390/ijms20164032.
VETVICKA V, VANNUCCI L, SIMA P, et al. Beta glucan: supplement or drug? from laboratory to clinical trials[J]. Molecules, 2019, 24(7): 1251. DOI: 10.3390/molecules24071251http://dx.doi.org/10.3390/molecules24071251.
ZHANG X D, ZHANG Y N, HE Y, et al. β-glucan protects against necrotizing enterocolitis in mice by inhibiting intestinal inflammation, improving the gut barrier, and modulating gut microbiota[J]. J Transl Med, 2023, 21(1): 14. DOI: 10.1186/s12967-022-03866-xhttp://dx.doi.org/10.1186/s12967-022-03866-x.
ZHONG X M, WANG G Q, LI F, et al. Immunomodulatory effect and biological significance of β-glucans[J]. Pharma-ceutics, 2023, 15(6): 1615. DOI: 10.3390/pharmaceutics 15061615http://dx.doi.org/10.3390/pharmaceutics15061615.
MIO K, OGAWA R, TADENUMA N, et al. Arabinoxylan as well as β-glucan in barley promotes GLP-1 secretion by increasing short-chain fatty acids production[J]. Biochem Biophys Rep, 2022, 32: 101343. DOI: 10.1016/j.bbrep. 2022.101343http://dx.doi.org/10.1016/j.bbrep.2022.101343.
LIU N Y, ZOU S W, XIE C H, et al. Effect of the β-glucan from Lentinus edodes on colitis-associated colorectal cancer and gut microbiota[J]. Carbohydr Polym, 2023, 316: 121069. DOI: 10.1016/j.carbpol.2023.121069http://dx.doi.org/10.1016/j.carbpol.2023.121069.
CHEN Y H, HAN B, GUAN X, et al. Enteric fungi protect against intestinal ischemia-reperfusion injury via inhibiting the SAA1-GSDMD pathway[J]. J Adv Res, 2024, 61: 223-237. DOI: 10.1016/j.jare.2023.09.008http://dx.doi.org/10.1016/j.jare.2023.09.008.
GARRET W S, GORDON J I, GLIMCHER L H. Homeostasis and inflammation in the intestine[J].Cell,2010 ,140(6):859-870.DOI: 10.1016/j.cell.2010.01.023http://dx.doi.org/10.1016/j.cell.2010.01.023.
PETERSON L W, ARTIS D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis[J]. Nat Rev Immunol, 2014, 14(3): 141-153. DOI: 10.1038/nri3608http://dx.doi.org/10.1038/nri3608.
WITTKOPF N, NEURATH M F, BECKER C. Immune-epithelial crosstalk at the intestinal surface[J]. J Gastroenterol, 2014, 49(3): 375-387. DOI: 10.1007/s00535-013-0929-4http://dx.doi.org/10.1007/s00535-013-0929-4.
WORTHINGTON J J. The intestinal immunoendocrine axis: novel cross-talk between enteroendocrine cells and the immune system during infection and inflammatory disease[J]. Biochem Soc Trans, 2015, 43(4): 727-733. DOI: 10.1042/BST20150090http://dx.doi.org/10.1042/BST20150090.
AOE S. Beta-glucan in foods and health benefits[J]. Nutrients, 2021, 14(1): 96. DOI: 10.3390/nu14010096http://dx.doi.org/10.3390/nu14010096.
HOLST J J. The physiology of glucagon-like peptide 1[J]. Physiol Rev, 2007, 87(4): 1409-1439. DOI: 10.1152/physrev.00034.2006http://dx.doi.org/10.1152/physrev.00034.2006.
YOON H S, CHO C H, YUN M S, et al. Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice[J]. Nat Microbiol, 2021, 6(5): 563-573. DOI: 10.1038/s41564-021-00880-5http://dx.doi.org/10.1038/s41564-021-00880-5.
SHI N, LI N, DUAN X W, et al. Interaction between the gut microbiome and mucosal immune system[J]. Mil Med Res, 2017, 4: 14. DOI: 10.1186/s40779-017-0122-9http://dx.doi.org/10.1186/s40779-017-0122-9.
JAYACHANDRAN M, CHEN J L, CHUNG S S M, et al. A critical review on the impacts of β-glucans on gut microbiota and human health[J]. J Nutr Biochem, 2018, 61: 101-110. DOI: 10.1016/j.jnutbio.2018.06.010http://dx.doi.org/10.1016/j.jnutbio.2018.06.010.
0
Views
0
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621
